A new EU regulation is meant to make clinical trials easier and more transparent, a pivotal tool in the fight against deadly diseases like cancer. But researchers in Germany warn that the country may lose its role as a leader in international medicine. EurActiv Germany reports.
Clinical trials are crucial for cancer researche, as demonstrated by numbers which scientists presented in Berlin on Tuesday (17 June).
Over the last three years, 31 drugs intended to treat cancer were approved by the European Medicines Agency (EMA).
Image: 31 drugs intended to treat cancer were approved by the European Medicines Agency (EMA) over the past three years. (Interpharma/Flickr)
To read the original article: Cancer research at a crossroads in Germany | EurActiv
